Tim Smith

These data highlighted the association of moderate air pollution exposure during pregnancy, infancy, and early childhood on pulmonary function at school age.

This model and its service components may be implemented in the future to allow for improvements to primary care programs, with the goal being benefits to patients with COPD.

Following this pooled analysis, there may be a need for additional research conducted to identify other targets for achievement of optimal repigmentation.

This supplemental new drug application for once-daily roflumilast foam follows positive results of the ARRECTOR phase 3 study.

These findings represent the first comprehensive research into the greater frequency of APS autoantibodies linked with treating psoriasis with TNF inhibitors.

These data suggest that the introduction of the concept of circadian syndrome contributes to greater understanding of risk management for those with psoriasis.

These data highlight results on efficacy, quality of life, and tolerability of DMF within routine clinical practice among those with plaque psoriasis.

These findings suggest that those with atopic dermatitis exacerbations may need to limit their oral corticosteroid duration for the purposes of limiting AEs.

In this Q&A interview, Stein Gold discusses new phase 3 findings regarding ruxolitinib cream 1.5% for patients 2 to 11 years old with atopic dermatitis.

These data suggest that risk of developing psoriatic arthritis among patients with different variants of psoriasis vary based on race and sex as well.

In this interview, Rosmarin discussed the results of a new post-hoc analysis of the TRuE-V1 and TRuE-V2 studies on treating younger vitiligo patients with ruxolitinib cream.

Awareness of these data may allow for dermatologists to better care for patients with anogenital pruritus as well as their families.

In this analysis, investigators highlighted the results of treating psoriasis with deucravacitinib in the phase 3 POETYK PSO-1 and PSO-2 trials.

This analysis was done to verify the hypothesis that psoriatic arthritis is primarily genetically predetermined and distinct from the condition of psoriasis.

These findings highlight clinician versus patient perceptions of chronic pruritus assessment using patient-reported outcome measures.

These data highlight the association between risk of developing polyneuropathy and the presence of psoriasis and psoriatic arthritis.

In this analysis, the investigators looked at the impacts of the IL-23 inhibitor guselkumab on patients with psoriasis.

These data suggest the necessity of additional research to explore seborrheic dermatitis as well as its variations among many diverse groups and populations.

These data highlight several key points about COPD and its prevalence, risk, and incidence among plaque psoriasis patients.

In this post-hoc analysis, investigators highlighted benefits of deucravacitinib among those with psoriasis compared to benefits of apremilast.

In this interview, Chovatiya discussed the recent FDA approval of roflumilast cream 0.15% for patients with eczema aged 6 years and older.

These data highlight the determinants and risk factors for admission to hospital among individuals with dermatological emergencies.

This decision by FDA officials resulted from the INTEGUMENT study findings which determined that once-daily roflumilast led to rapid eczema clearance and significant disease reductions.

In this summary of major news in pulmonology covered in June 2024, approvals by the FDA, new episodes of Lungcast, news on COPD, and more are highlighted.

These findings also highlighted the necessity of identifying the clinically relevant comorbidities of asthma and allergic rhinitis in a proactive manner.

Arcutis Biotherapeutics announced the update and indicated the FDA was working to finalize the action letter on July 09, 2024, which was 2 days after the assigned PDUFA date of July 07, 2024.

These updated guidelines by the AAAAI and ACAAI Joint Task Force incorporate additional research regarding treatment options for eczema.

These findings confirm the ways in which patient responses in the head and neck areas contribute to modifications in life quality among those with eczema.

This retrospective study highlighted the results of Singaporean atopic dermatitis patients aged 18 years and below who had undergone phototherapy.

This analysis from Spain assessed the short-term effectiveness and safety of abrocitinib within a real-world setting for those with moderate-to-severe eczema.